Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years.

Emma Guttman-YasskyKenji KabashimaDelphine Staumont-SalleWalter K NahmSylvia PauserJoel Correa Da RosaBritta Cathrina MartelDaniel Elenius MadsenMads RøpkePetra ArlertLouise SteffensenAndrew BlauveltKristian Reich

Published in: Allergy (2024)

NCT03131648, NCT03587805.

Keyphrases

atopic dermatitis
oxidative stress
cancer therapy
drug delivery